Search Results

Crown Bioscience has announced that its collaborative work with HanX Biopharmaceutical Co., Ltd. (“HanX”), employing a unique and broad portfolio of preclinical modeling in support of HanX’s successful FDA Investigational New Drug (IND) application, has been published in Scientific Reports, a journal within the Nature portfolio.

Hanx Biopharmaceuticals, Inc. (HanxBio), announced that the company has received Investigational New Drug (IND) approval to start clinical trial of the potentially first-in-class recombinant anti-CD47/PD-1 bispecific antibody (BsAb), HX009, in Patients with relapsed/refractory Lymphoma.

Navidea Biopharmaceuticals, Inc., a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced it will be hosting a virtual meeting of its stockholders at 1pm ET on Monday, July 8th, 2024.

Provectus Biopharmaceuticals, Inc. announced that its 2024 annual stockholder meeting, including meeting activities and a company update, will be accessible by Zoom Webinar.

Eiger BioPharmaceuticals, Inc. today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-30.

Biopharmaceutical Market Outlook 2024-2032:

KBI Biopharma, Inc., a JSR Life Sciences company and cGMP contract development and manufacturing organization, and Argonaut Manufacturing Services, Inc., a cGMP contract manufacturing organization serving the biopharmaceutical and diagnostics industries, announced a strategic alliance offering biopharmaceutical clients with end-to-end drug substance and drug product manufacturing solutions.

Navidea Biopharmaceuticals, Inc. announced that it filed a Form 15 with the Securities and Exchange Commission to deregister its common stock, preferred stock purchase rights and Series K preferred stock under Section 12 of the Securities Exchange Act of 1934, as amended, and to suspend its reporting obligations under Section 15 of the Exchange Act.